Recent reports and guideline changes suggest some medical tests should be delayed, avoided, or done less often: _ MAMMOGRAM: Most women don't need a mammogram in their 40s and they should get one every two years starting at 50, according to the U.S. Preventive Services ...

Watson Pharmaceuticals Inc. said the Food and Drug Administration approved a six-month dose of the prostate cancer drug Trelstar, which already was available in one- and three-month doses. Trelstar is developed by Debiopharm Group of Switzerland and marketed by Watson. Watson plans to launch the six-month dose in ...

WASHINGTON (Reuters) - The most commonly used tool for detecting prostate cancer, routine PSA screening, has become "a hugely expensive public health disaster," its discoverer said on Wednesday. Dr. Richard Ablin of the University of Arizona joined the ongoing debate over the blood test, saying the screening procedure is too costly and ineffective. "I never dreamed that my discovery four decades ...

NEW YORK (Reuters Health) - New research suggests that the type of specialist a prostate cancer patient sees -- rather than the patient's own preference -- may determine the treatment he receives. This is problematic, the study's authors say, because none of the options now available for treating localized prostate cancer have been shown to be any better than the others ...